Product Data

D12079B

Description

RD Western Diet

Used in Research

Obesity
Diabetes
Osteoporosis
Hypertension
Atherosclerosis
Metabolic Syndrome

Packaging

Product is packed in 12.5 kg box. Each box is identified with the product name, description, lot number and expiration date.

Lead Time

IN-STOCK- Ready for next day shipment.

Gamma-Irradiation

Yes. Add 10 days to delivery time.

Form

Pellet, Powder, Liquid

Shelf Life

Most diets require storage in a cool dry environment. Stored correctly they should last 3-6 months.

Control Diets

Custom diets available on request.

Formula

Product #		D12079B	
		gm%	kcal%
Protein		20	17
Carbohydrate		50	43
Fat		21	41
	Total		100
	kcal/gm	4.7	

Ingredient	gm	kcal
Casein, 80 Mesh	195	780
DL-Methionine	3	12
Corn Starch	50	200
Maltodextrin 10	100	400
Sucrose	341	1364
Cellulose	50	0
Milk Fat, Anhydrous*	200	1800
Corn Oil	10	90
Mineral Mix S10001	35	0
Calcium Carbonate	4	0
Vitamin Mix V10001	10	40
Choline Bitartrate	2	0
Cholesterol, USP*	1.5	0
Ethoxyquin	0.04	0
Total	**1001.54**	**4686**

*Anhydrous milk fat typically contains approximately 0.3% cholesterol. On this basis, D12079B contains approximately 0.21% cholesterol.
Formulated by E. A. Ulman, Ph.D., Research Diets, Inc., October 12, 1995. Diet formulated to match Teklad Western Diet #TD88137, except that 1% Corn Oil replaces 1% Butter Fat.

RESEARCH DIETS INC.™
www.ResearchDiets.com

Research Diets, Inc.
20 Jules Lane
New Brunswick, NJ 08901
Tel: 732.247.2390
Fax: 732.247.2340
info@researchdiets.com

Copyright © 2006 Research Diets, Inc. All rights reserved. D12079B

REFERENCES

2/15/06

D12079B

1. Beigneux, A.P., et al. ATP-Citrate lyase deficiency in the mouse. Journal of Biological Chemistry. 279:9557-9564, 2004.
2. Bhat, B.G. et al. Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435. Journal of Lipid Research. 44:1614-1621, 2003.
3. Collins, A.R. et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb. Vasc. Biol. 21:365-371, 2001.
4. Davis, H.R., et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibit the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb. Vasc. Biol. 21:2032-2038, 2001.
5. Lemaître, V., et al. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation. 107:333-338, 2003.
6. Lemaître, V. et al. ApoE knockout mice expressing human matrix metalloproteinase-1 macrophages have less advanced atherosclerosis. Journal of Clinical Investigation. 107:1227-1234, 2001.
7. Ogus, S. et al. Hyperleptinemia precipitates diet-induced obesity in transgenic mice overexpressing leptin. Endocrinology. 144:2865-2869, 2003.
8. Park, Tae-Sik, et al. Inhibition of sphingomyelin synthesis reduces atherogeneesis in apolipoprotein E-knockout mice. Circulation. 110:3465-3471, 2004.
9. Seli, E., et al. Estradiol suppresses vascular monocyte chemotactic protein-1 expression during early atherogenesis. Am. J. Obstet. Gynecol. 187:1544-1549, 2002.

Research Diets, Inc.
20 Jules Lane
New Brunswick, NJ 08901
Tel: 732.247.2390
Fax: 732.247.2340
info@researchdiets.com